Literature DB >> 21103860

Supratherapeutic oseltamivir levels during continuous dialysis: an expected risk.

Gregory A Eschenauer, Simon W Lam.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21103860     DOI: 10.1007/s00134-010-2080-5

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  5 in total

1.  An in vitro study of the elimination of oseltamivir carboxylate by haemofiltration.

Authors:  Pascale C Gruber; Qi Tian; Charles D Gomersall; Gavin M Joynt; Gordon Y S Choi
Journal:  Int J Antimicrob Agents       Date:  2007-04-24       Impact factor: 5.283

Review 2.  Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.

Authors:  G He; J Massarella; P Ward
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 3.  Pharmacokinetic changes during extracorporeal membrane oxygenation: implications for drug therapy of neonates.

Authors:  Marcia L Buck
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 4.  Principles of antibacterial dosing in continuous renal replacement therapy.

Authors:  Gordon Choi; Charles D Gomersall; Qi Tian; Gavin M Joynt; Ross Freebairn; Jeffrey Lipman
Journal:  Crit Care Med       Date:  2009-07       Impact factor: 7.598

5.  Oseltamivir carboxylate accumulation in a patient treated by haemodiafiltration and extracorporeal membrane oxygenation.

Authors:  Florian Lemaitre; Charles-Edouard Luyt; François Roullet-Renoleau; Ania Nieszkowska; Noël Zahr; Christine Fernandez; Robert Farinotti; Alain Combes
Journal:  Intensive Care Med       Date:  2010-04-08       Impact factor: 17.440

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.